Vanda Pharmaceuticals (VNDA) EBIAT (2016 - 2025)
Historic EBIAT for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$141.2 million.
- Vanda Pharmaceuticals' EBIAT fell 277432.82% to -$141.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$220.5 million, marking a year-over-year decrease of 106652.91%. This contributed to the annual value of -$220.5 million for FY2025, which is 106652.91% down from last year.
- Latest data reveals that Vanda Pharmaceuticals reported EBIAT of -$141.2 million as of Q4 2025, which was down 277432.82% from -$22.6 million recorded in Q3 2025.
- Vanda Pharmaceuticals' EBIAT's 5-year high stood at $9.7 million during Q2 2021, with a 5-year trough of -$141.2 million in Q4 2025.
- Over the past 5 years, Vanda Pharmaceuticals' median EBIAT value was -$1.1 million (recorded in 2023), while the average stood at -$9.9 million.
- In the last 5 years, Vanda Pharmaceuticals' EBIAT soared by 167983.54% in 2021 and then tumbled by 398613.14% in 2024.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBIAT stood at $7.1 million in 2021, then fell by 3.07% to $6.9 million in 2022, then tumbled by 134.98% to -$2.4 million in 2023, then tumbled by 104.67% to -$4.9 million in 2024, then tumbled by 2774.33% to -$141.2 million in 2025.
- Its EBIAT was -$141.2 million in Q4 2025, compared to -$22.6 million in Q3 2025 and -$27.2 million in Q2 2025.